Longitudinal in vivo micro-CT assessment in osteopenic women demonstrated that risedronate reduced the deterioration of cortical bone
Dieter Felsenberg(Charité - Universitätsmedizin Berlin), R. Rizzolli(University Hospital of Geneva), Alice M.S. Cheung(Duke-NUS Medical School), T. Thomas, Lynn Darbie, G D'Alò, Michel Laroche(Royal Bank of Canada), R. Charpulat(Hôpital Edouard Herriot), Edward Morris(University of East Anglia), José Zanchetta(Universidad del Salvador), B. Borah, Ego Seeman(The University of Melbourne)
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k